A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors

Amy Rosenfeld*, Morris Kletzel, Reggie E Duerst, David Jacobsohn, Paul Haut, Joanna Lynn Weinstein, Alfred W Rademaker, Colleen Schaefer, Lauren Evans, Molly Fouts, Stewart Goldman

*Corresponding author for this work

Research output: Contribution to journalArticle

16 Scopus citations


High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m2) 9 3 days, etoposide (250 mg/m2) 9 3 days, and thiotepa (300 mg/m2) 9 3 days. Patients without progression or excessive toxicity (n = 11), received regimen &has2 with melphalan (60 mg/m2) 9 3 days and cyclophosphamide (1,500 mg/m2) 9 4 days. Projected overall/event-free survival for the 19 patients was 51/37% and 34/28% at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.

Original languageEnglish (US)
Pages (from-to)247-255
Number of pages9
JournalJournal of Neuro-Oncology
Issue number2
StatePublished - Apr 1 2010



  • Chemotherapy
  • Hematopoietic stem cell rescue
  • Myeloablative
  • Pediatric high risk and brain tumors
  • Pediatric recurrent brain tumors

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this